Mitsui Ventures NEWS

NEWS 2006

[03/31/2006]

CELL BIOSCIENCES ANNOUNCES THE APPOINTMENT OF BLAINE BOWMAN AS LEAD DIRECTOR.


Palo Alto, CA March 31, 2006

Cell BioSciences Inc. today announced that A. Blaine Bowman has joined its Board as Lead Director.

Mr. Bowman brings an unusual combination of strategic thinking and operating experience in analytical instrumentation, said Linda Cahill, CEO. The investment group and management team at Cell BioSciences look forward to having an executive of this caliber helping to guide us as we begin the commercialization of our first product in 2006."

Blaine Bowman was most recently the President and Chief Executive Officer of Dionex Corporation (NASDAQ: DNEX), a leading developer and manufacturer of laboratory and process analytical systems and related products. Mr. Bowman joined the company in 1977. Under his leadership, Dionex grew from $1 million in sales to over $180 million and is widely respected for its innovative products and solid growth. Earlier, he was a management consultant with McKinsey and Company and a product engineer at Motorola Semiconductor Products Division. Mr. Bowman holds a B.S. Degree in Physics from Brigham Young University and an MBA from Stanford University Graduate School of Business.

About Cell Biosciences

Cell Biosciences is a provider of life science instrumentation systems for protein measurement and identification. The Company designs, manufactures, markets and supports the nano-fluidics immunoassay platform called the Firefly? 3000, providing a powerful tool for scientific investigation in biochemistry, hematology, immunology, and oncology. The Firefly system automates and streamlines the tedious technique of western blotting by eliminating the blotting step and substantially reducing the number of handling steps. Cell Biosciences is located in Palo Alto, CA and can be reached by phone (650 859 1485); on its website (www.cellbiosciences.com) or by email (sales@cellbiosciences.com).

http://www.cellbiosciences.com/

Forward-Looking Statements

Statements included in this press release that are not historical in nature may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of such forward-looking statements include, without limitation, statements regarding any new instruments or tools, any benefits for customers to be derived from new instruments or tools, and the ability of Cell Bioscience’s products to enhance research or achieve market acceptance. Any such forward-looking statements involve risks and uncertainties and reflect Cell Bioscience’s judgment as of the date of this release. The Company claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

News Release

Taro Inaba 06/17/2008 | Taro Inaba
Boehringer Ingelheim announced an agreement to acquire Actimis Pharmaceuticals, Inc. one of our portfolio firms.

Nobuhiro Shimizu 11/01/2007 | Nobuhiro Shimizu 11/01/2007 | Nobuhiro Shimizu
【Announcement of the Establishment of Beijing Office】

We are pleased to announce that Mitsui Ventures has opened a new office in Beijing in September2007.

Taro Inaba 07/18/2007 | Taro Inaba 07/18/2007 | Taro Inaba
Mitsui Ventures Launching a New Approach to Seed Financing